Multiparameter analysis of tumor response to anti-PD-1 therapy with integrated PET/MRI in lung cancer
Project/Area Number |
19K08119
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 52040:Radiological sciences-related
|
Research Institution | University of Fukui |
Principal Investigator |
Umeda Yukihiro 福井大学, 学術研究院医学系部門(附属病院部), 講師 (80401975)
|
Co-Investigator(Kenkyū-buntansha) |
石塚 全 福井大学, 学術研究院医学系部門, 教授 (50302477)
岡沢 秀彦 福井大学, 高エネルギー医学研究センター, 教授 (50360813)
|
Project Period (FY) |
2019-04-01 – 2023-03-31
|
Project Status |
Completed (Fiscal Year 2022)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | FLT-PET / 非小細胞肺がん / 免疫治療 / 免疫チェックポイント阻害剤 / 肺癌 / FDG / FLT / PET / MRI / 効果判定 |
Outline of Research at the Start |
①統合型PET/MRIを用い、非小細胞肺癌に対するPD-1抗体治療の早期効果判定を行う。治療前後にFLT及びCu-ATSM-PET/MRIを行い、PET及びMRIのパラメーターを測定し、これらとresponse evaluation criteria in solid tumors (RECIST)による奏効との関連、無増悪生存期間、全生存期間との関連を検討する。 ②PD-1抗体治療後早期に増大が見られた場合、診断の目的で再生検を行い、治療前後の検体においてPD-1及びPD-L1の発現の程度やCD8+T細胞や制御性T細胞の腫瘍内密度を評価し、腫瘍内部の免疫反応の差を評価し画像変化の意味付けする。
|
Outline of Final Research Achievements |
Anti-programmed death-1 (PD-1) therapy has shown clinical success in patients with advanced non-small cell lung cancer (NSCLC). However, it is difficult to evaluate the early response to anti-PD-1 therapy. We determined whether changes in 3′-deoxy-3′- [18F]-fluorothymidine (18F-FLT) PET parameters before and soon after treatment initiation predicted the therapeutic effect of anti-PD-1 antibody. Patients with non-progressive disease (non-PD) had significantly decreased TLP at 2 weeks, and decreased SUVmax, PTV, and TLP at 6 weeks, compared to those with PD. Changes in 18F-FLT PET parameters may have value as an early predictive biomarker for the response to anti-PD-1 therapy in patients with NSCLC. However, it should be noted that pseudoprogression was observed in 18F-FLT PET imaging at 2 weeks after treatment initiation.
|
Academic Significance and Societal Importance of the Research Achievements |
治療2週後でのFLT集積の変化は、その後の治療効果を中程度予測した。しかし、奏効した患者の37.5%にproliferative pseudoprogressionが認められた。治療6週後の18F-FLT集積の変化は、より強くその後の治療効果と関連した。PD-1抗体による炎症細胞の増殖の程度を測定することで、診断精度を高められる可能性がある。
|
Report
(5 results)
Research Products
(10 results)
-
-
-
-
[Journal Article] Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer.2020
Author(s)
Umeda Y, Morikawa M, Anzai M, Ameshima S, Kadowaki M, Waseda Y, Shigemi H, Tsujikawa T, Kiyono Y, Okazawa H, Ishizuka T.
-
Journal Title
J Immunother Cancer
Volume: 8
Issue: 1
Pages: e000349-e000349
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.2020
Author(s)
Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, Osaki T, Kasahara N, Uchino J, Sugiyama T, Ishihara S, Ishii H, Naruse I, Mori K, Kotake M, Kanazawa K, Minato K, Kagamu H, Kaira K.
-
Journal Title
Cancer Chemother Pharmacol
Volume: 85
Issue: 4
Pages: 761-771
DOI
Related Report
Peer Reviewed
-
[Journal Article] Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged > 75 years) with non-small cell lung cancer.2020
Author(s)
Imai H, Wasamoto S, Yamaguchi O, Suzuki K, Sugiyama T, Uchino J, Minemura H, Osaki T, Ishii H, Umeda Y, Mori K, Kotake M, Kagamu H, Morozumi N, Taniguchi H, Kasai T, Minato K, Kaira K.
-
Journal Title
Journal of Cancer Research and Clinical Oncology
Volume: 146
Issue: 2
Pages: 457-466
DOI
Related Report
Peer Reviewed
-
[Journal Article] The vertebral 3'-deoxy-3'-18F-fluorothymidine uptake predicts the hematological toxicity after systemic chemotherapy in patients with lung cancer.2019
Author(s)
Umeda Y, Tsujikawa T, Anzai M, Morikawa M, Waseda Y, Kadowaki M, Shigemi H, Ameshima S, Mori T, Kiyono Y, Okazawa H, Ishizuka T.
-
Journal Title
Eur Radiol
Volume: 29
Issue: 7
Pages: 3908-3917
DOI
Related Report
Peer Reviewed
-
-
-